C Diff Drug Development

Happy to share our work in @JAMANetworkOpen In our study patients treated with SER-109 (an oral microbiome therapeutic) had significantly greater improvements in disease-specific HRQOL scores compared with patients treated with placebo through 8 wks #cdiff https://t.co/zL1iUg3LBz pic.twitter.com/77wCrrTIlv— Abhishek Deshpande (@abhishek_dp) January 30, 2023

Infections by Clostridioides difficile , a bacterium that targets the large intestine (colon), impact a significant number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can inhibit the biocatalytic activity of these toxins repres …

Clostridioides difficile infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a Bacillus velezensis strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the rec …

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

The gut microbiome plays a critical but poorly understood role in how drugs work or don't work in the body. It also presents therapeutic possibilities unto itself.

SOMERVILLE, Mass., Jan. 24, 2023 -- Finch Therapeutics Group, Inc. today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection and focus on... | January 24, 2023

.@ServatusLtd's drug development platforms contain engineered proteins for the treatment of autoimmune diseases and live biotherapeutics (LBPs) for the treatment of inflammatory conditions and bacterial infections including #IBD, #CDiff and H. pylori. https://t.co/eUgiukdHkL— MTIG (@MTIG_News) January 23, 2023

In recent years, there has been a growing interest in the use of novel antimicrobial agents able to inhibit or kill food-borne bacteria or to interrupt the onset of food spoilage. Crocus sativus L. petals, typically considered as waste obtained from saffron spice production, could be a source …

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

MELBOURNE, Australia, Jan. 17, 2023 -- Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic... | January 17, 2023

Clostridioides difficile is a gram-positive bacterium which is associated with different gastrointestinal related infections, and the numbers of cases related to it are continuously increasing in the past few years. Owing to high prevalence and development of resistance towards available anti …

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.

Human body can digest only a few sugars with a low degree of polymerization. The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health. Adlay is a medicinal and food homologous crop. The study aims to determine whether de …

According to recent research conducted at several member hospitals that are part of Trinity Health and published in Infection Control and Hospital Epidemiology, optimized environmental cleaning is the key to effectively reducing C. diff transmission inside hospitals.

Nature Reviews Gastroenterology & Hepatology - The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from...

Antivirulence agents targeting endospore-transmitted Clostridioides difficile infections are urgently needed. C. difficile-specific DNA adenine methyltransferase (CamA) is required for efficient sporulation and affects persistence in the colon. The active site of CamA is conserved and …

Treatment efficacy of fecal microbiota-based live biotherapeutics (RBX2660) for the prevention of recurring Clostridioides difficile infection

RBX2660 is the first ever live microbiota therapeutic approved by the FDA.

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

Read the final report from the phase 2b PUNCH CD2 study of RBX2660, an investigational live biotherapeutic to reduce C. difficile infection recurrence, showing 24-month safety and meaningful efficacy for 1 dose v placebo - https://t.co/hyVJ0cABVR#cdiff #microbiome— Infectious Diseases and Therapy (@InfectDis_Ther) December 22, 2022

An insight into the Clostridioides difficile infection-related diarrhea

Clostridioides difficile infection (CDI), recurrently reported as an urgent threat owing to its increased prevalence and mortality, has attracted significant attention. As the use of antibiotics to treat CDI has many limitations, such as high recurrence rate, the need to actively seek and develop ot …

ClinicalTrials.gov: NCT02299570.

Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Microbiome

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.